News
Why Adamas Pharmaceuticals Inc. Jumped Higher Today
Adamas Pharmaceuticals (NASDAQ: ADMS) closed up 21% on Monday, after Point72 Asset Management disclosed in an SEC document on Friday after the bell that it boosted its stake in the drugmaker.The....
Better Buy: Intuitive Surgical, Inc. vs. Johnson & Johnson
With multiple catalysts likely to fuel its growth, the healthcare sector is fertile ground from which investors can reap sizable profits -- if you know where to look.To help you in this regard,....
Better Buy: Intuitive Surgical, Inc. vs. Johnson & Johnson
With multiple catalysts likely to fuel its growth, the healthcare sector is fertile ground from which investors can reap sizable profits -- if you know where to look.To help you in this regard,....
Global Blood Therapeutics Inc. Jumped as Much as 14% on This News
Shares of San Francisco-based Global Blood Therapeutics (NASDAQ: GBT), a small-cap developer of experimental therapies focused on treating blood-based disorders, rocketed higher by as much as 14%....
Celgene Corporation Has "Optionality and Opportunity"
Celgene (NASDAQ: CELG) got crushed after announcing third-quarter earnings, saying revenue would come in at the bottom of previous guidance, and lowering its 2020 guidance. All things considered,....
Why TransEnterix Stock Is Rebounding Today
TransEnterix (NYSEMKT: TRX), a small-cap robotic-surgery company, is on the rebound today with its shares up by 21.41% on heavy volume, as of 11:05 a.m. EDT.Prior to today's double-digit move,....
Why TransEnterix Stock Is Rebounding Today
TransEnterix (NYSEMKT: TRX), a small-cap robotic-surgery company, is on the rebound today with its shares up by 21.41% on heavy volume, as of 11:05 a.m. EDT.Prior to today's double-digit move,....
2 Top Pharma Stocks on Sale This Week
Like most investors, I love a good bargain. So when the top pharma stocks Celgene Corporation (NASDAQ: CELG) and GlaxoSmithKline plc (NYSE: GSK) both crashed last week, it definitely caught my....
2 Top Pharma Stocks on Sale This Week
Like most investors, I love a good bargain. So when the top pharma stocks Celgene Corporation (NASDAQ: CELG) and GlaxoSmithKline plc (NYSE: GSK) both crashed last week, it definitely caught my....
The 3 Best Diabetes Stocks to Buy in 2018
Diabetes is a chronic condition that occurs when the body loses its ability to properly metabolize sugar. Without treatment, people with diabetes end up with too much sugar flowing through their....
3 Reasons I've Been Aggressively Buying Intercept Pharmaceuticals
I admit it: I love trying to catch a falling knife. Sometimes you get sliced in the process, while at other times you leave vindicated by having gone against the grain. My belief is that small-cap....
The 3 Best Diabetes Stocks to Buy in 2018
Diabetes is a chronic condition that occurs when the body loses its ability to properly metabolize sugar. Without treatment, people with diabetes end up with too much sugar flowing through their....
How to Invest in Healthcare
Ten thousand Americans will turn 65 years old every day from now through 2029. As those Americans age, they will transform our country's healthcare system -- to the tune of a 5.8% annual increase....
How to Invest in Healthcare
Ten thousand Americans will turn 65 years old every day from now through 2029. As those Americans age, they will transform our country's healthcare system -- to the tune of a 5.8% annual increase....
ResMed's Sales and Profits Rise
ResMed (NYSE: RMD), a medical device marker focused on continuous positive airway pressure (CPAP) machines and accessories, reported its fiscal first-quarter results on Thursday, Oct. 26. The....
5 Things You Need to Know From Gilead Sciences' Q3 Update
You could probably fit the number of people surprised by Gilead Sciences' (NASDAQ: GILD) third-quarter results inside a phone booth -- if you could even find one. Hepatitis C virus (HCV) drug....
5 Things You Need to Know From Gilead Sciences' Q3 Update
You could probably fit the number of people surprised by Gilead Sciences' (NASDAQ: GILD) third-quarter results inside a phone booth -- if you could even find one. Hepatitis C virus (HCV) drug....
5 Things You Need to Know From Gilead Sciences' Q3 Update
You could probably fit the number of people surprised by Gilead Sciences' (NASDAQ: GILD) third-quarter results inside a phone booth -- if you could even find one. Hepatitis C virus (HCV) drug....
Ending Obamacare's Cost-Sharing Reductions Will Lead to This Ironic Result
With open enrollment for the Affordable Care Act (ACA) just days away, you're liable to notice that Obamacare (the more common name for the ACA) will look a lot different in the upcoming year.Most....
A Me-Too Push By Biopharma Is Crowding the Psoriasis Market
A wave of R&D is leading to next-generation psoriasis drugs that work better than ever. That's great news for patients desperate for new treatment options, but it's bad news for biopharma....
A Me-Too Push By Biopharma Is Crowding the Psoriasis Market
A wave of R&D is leading to next-generation psoriasis drugs that work better than ever. That's great news for patients desperate for new treatment options, but it's bad news for biopharma....
3 Bright Spots in Merck's Q3 Results
You only had to look at Merck's (NYSE: MRK) stock movement to know that the big drugmaker's third-quarter results weren't too great. Merck's share price dropped after the company reported a 2%....
3 Bright Spots in Merck's Q3 Results
You only had to look at Merck's (NYSE: MRK) stock movement to know that the big drugmaker's third-quarter results weren't too great. Merck's share price dropped after the company reported a 2%....
3 High-Yield Dividend Aristocrat Stocks
If dividend stocks were like golf, there would be an elite group of stocks with green jackets like golfing greats who win the Masters tournament get to wear. This group of winners is called the....
Vertex Pharmaceuticals Incorporated: One Eye on Earnings, One on the Pipeline
Vertex Pharmaceuticals (NASDAQ: VRTX) reported solid third-quarter earnings, with sales of its cystic fibrosis drugs up 34% year over year. Nevertheless, investors rightfully have one eye on the....